The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Updated: Manawa shares sag with Contact deal odds
Finance

Updated: Manawa shares sag with Contact deal odds

Forsyth Barr analysts said chances are now 50/50. 

Pattrick Smellie 07 Feb 2025
Forsyth Barr on Spark's 'incumbent's dilemma'
Finance

Forsyth Barr on Spark's 'incumbent's dilemma'

Falling market share and margins in the broadband market look entrenched.

Pattrick Smellie 05 Feb 2025
Unscrambling EGS investment in Trump's world
Finance

David Chaplin: Unscrambling EGS investment in Trump's world

The US rush from ESG investments labels is well under way.

David Chaplin 05 Feb 2025
Coal and gold added to critical minerals list
Finance

Coal and gold added to critical minerals list

Banks and insurance companies threatened with regulatory retaliation if they block mining.

Ian Llewellyn 31 Jan 2025